Chemistry:Andecaliximab
From HandWiki
Short description: Monoclonal antibody
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Chimeric (mouse/human) |
| Target | gelatinase B |
| Clinical data | |
| Other names | GS-5745 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6396H9868N1680O2010S46 |
| Molar mass | 143933.81 g·mol−1 |
Andecaliximab (INN;[1] development code GS-5745) is an experimental humanized monoclonal antibody designed for the treatment of cancer and inflammatory diseases.
This drug was developed by Gilead Sciences, Inc.[2]
Phase II and phase III trials for gastric cancer or gastroesophageal junction adenocarcinoma completed in 2019.
References
- ↑ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115". WHO Drug Information 30 (2). https://www.who.int/medicines/publications/druginformation/innlists/PL115.pdf.
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Andecaliximab, American Medical Association.
 |  |
